Altimmune, Inc.

ALT Healthcare Biotechnology

Altimmune, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41,000.00, up 105.0% from fiscal 2024. In the quarter to June 2026, revenue grew 520.0%, EPS grew 55.6%, free cash flow fell 25.3% and total debt rose 142.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.48 0.08 −3.13%
Market cap
$498.0M
P/E
0.0×
Fwd P/E
−3.9×
Dividend yield
—
F-score
4/9
Altman Z
0.23
Beneish M
−3.17
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 4 — —
ROE
(52.61%) (50.57%) (42.75%) (28.87%)
ROA
(45.82%) (42.03%) (36.96%) (25.58%)
ROIC
0.00% 0.00% 0.00% (34.30%)
Return on Tangible Assets
(41.07%) (33.43%) (28.15%) (28.46%)
Average Days of Receivables
25,404.00 13,782.72 0.00 0.00
Free Cash Flow per Share
(0.74) (0.77) (0.58) (0.41)
Free Cash Flow
(66.36) (67.55) (71.67) (76.56)
Other line items

Show all line items

Columns are period end dates